摘要
目的探讨阿托伐他汀对急性冠状动脉综合征患者血清C反应蛋白的影响。方法选择急性冠状动脉综合征患者46人,随机分为阿伐他汀组和常规治疗组,阿伐他汀组在常规治疗的基础上加用阿托伐他汀每天40mg,常规治疗组采用常规治疗。分别于治疗前和治疗后两周测定血清C反应蛋白和血脂水平,比较其差异。结果46例急性冠状动脉综合征患者中,不稳定心绞痛17例,急性心肌梗死29例。血清C反应蛋白水平,心绞痛者为1.37±0.52 g/L,心肌梗死者为2.23±0.45 g/L,均高于正常对照组的0.30±0.22 g/L(P<0.05),心肌梗死患者较心绞痛者C反应蛋白升高显著(P<0.05)。阿托伐他汀治疗两周,血清C反应蛋白水平由1.88±0.45 g/L降至0.52±0.22 g/L,治疗前后相比有显著性差异(P<0.05)。常规治疗组血清C反应蛋白水平由1.85±0.50 g/L降至1.77±0.60 g/L,治疗前后相比无显著性差异(P>0.05)。结论C反应蛋白可能参与动脉粥样硬化的形成,短期使用阿托伐他汀即能明显降低急性冠状动脉综合征患者的血浆C反应蛋白水平,提示阿托伐他汀调脂作用之外还有抗炎作用。
Aim To approach the effect of atorvastatin on C reactive protein（ CRP） of patient with acute coronary syndrome（ACS）. Methods 46 eases with ACS,whieh were determined CRP level pre- and post-treatment two weeks, respectively,and compared its difference, were randomly divided into therapeutic drug group and control group, therapeutic group was treated with atorvastatin 40mg daily based on routine treatment（control group）. Results 46 cases include 17 cases unstable angina and 29 cases acute myocardial infaretion. The CRP level was 1.37 ± 0.52 g/L in angina patient and was 2.23 ± 0.45 g/ L in the patient with acute myecardial infarction. And it were higher than that of normal control（0.30 ± 0.22 g/L） （ P 〈 0.05 ）, it was significant advanced of CRP in the patient with myocardial infarction than that of the patient with angina （ P 〈 0.05 ）. The blood serum CRP level decreased from 1.88 ± 0.45 g/L to 0.52 ± 0.22 g/L （ P 〈 0.05 ） in therapeutic group and has no changes in the control group of the bloed serum CRP level decreased from 1.85± 0.50 g/L to 1.77 ±0.60 g/L （ P 〉 0.05）. Conclusion The CRP is possible to participate the formation of atheresclerosis, and the CRP level was set down obviously of the patients with ACS,it is shown that the atorvastatin can reduce lipid besides anti-inflammatory effect.
出处
《中国动脉硬化杂志》
CAS
CSCD
2005年第5期644-645,共2页
Chinese Journal of Arteriosclerosis
